What We Look For

Most of the ideasbi³will support will feature the following properties:

  • Innovative biology with disease-modifying potential
  • Drug prototypes: Lead-stage molecules that are no more than 3 – 4 years away from IND
  • Milestone-driven research plan that outlines a clear path toward transition into development and can be completed in 2 to 3 years for a maximum of $10 M
  • Relevant to a therapeutic area of interest to Biogen Idec: neurology, oncology, immunology, acute cardiovascular
  • Protein-based therapeutic or a small molecule with well-characterized biology and a rational SAR strategy
  • Committed scientists/founders willing to play a substantial role in the company